Chanazone 1 g, Oral Powder for Horses

Land: Storbritannien

Språk: engelska

Källa: VMD (Veterinary Medicines Directorate)

Aktiva substanser:

Phenylbutazone

Tillgänglig från:

Chanelle Pharmaceuticals Manufacturing Ltd

ATC-kod:

QM01AAO1

INN (International namn):

Phenylbutazone

Läkemedelsform:

Oral powder

Receptbelagda typ:

POM-V - Prescription Only Medicine – Veterinarian

Terapeutisk grupp:

Horses

Terapiområde:

Anti Inflammatory NSAID

Bemyndigande status:

Authorized

Tillstånd datum:

2016-03-15

Produktens egenskaper

Revised: February 2021
AN: 00673/2020
Page 1 of 7
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Chanazone 1 g, oral powder for horses.
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each sachet of 5 g contains:
ACTIVE SUBSTANCE:
Phenylbutazone 1 g.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oral powder
An off white to yellowish coloured granular powder
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Horses (non-food producing horses).
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
The product is indicated for the treatment of musculoskeletal
conditions in the horse
where relief from pain and a reduction in the associated inflammation
is required, e.g. in
lameness associated with osteoarthritic conditions, bursitis,
laminitis and soft tissue
inflammation, particularly where continued mobility is considered
desirable.
It is also of value in limiting post surgical inflammation, myositis
and other soft tissue
inflammation.
Phenylbutazone powder can be used as an anti-pyretic where this is
considered
advisable e.g. in viral respiratory infections.
4.3
CONTRAINDICATIONS
Revised: February 2021
AN: 00673/2020
Page 2 of 7
Do not use in cases of known hypersensitivity to the active substance
or to any of the
excipients
Do not use in animals suffering from cardiac, hepatic or renal
disease, where there is the
possibility of gastro-intestinal ulceration or bleeding or where there
is evidence of a blood
dyscrasia.
Do not use in animals suffering from thyroid disease.
Do not use in animals with severe hypertonia.
Do not use in animals with lesions in the intestinal mucosa, caused by
parasitic
infestations.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
The clinical effects of phenylbutazone can be evident for at least
three days following
cessation of therapy. This should be borne in mind when examining
horses for
soundness.
The International Federation for Equestrian Sports (FEI) regards
phenylbutazone as
prohibited substance in the context of a participation of the